Cargrilintide 10mg
Appetite suppression
$75.00
Out of stock
Cargrilintide
For Research Purposes Only – Not for Human Consumption
Product Overview
Cargrilintide is a synthetic amylin analogue currently under investigation for potential roles in metabolic research. It is designed to mimic and extend the biological activity of endogenous amylin. Cargrilintide is being studied for its effects on satiety, gastric emptying, and metabolic regulation.
Intended Use
This material is supplied strictly for in vitro and in vivo laboratory research use only. It is not approved for use in humans, animals, or for diagnostic or therapeutic applications.
Specifications
Compound: Cargrilintide
Form: Lyophilized powder
Storage: Store at -20°C; protect from light and moisture
Solubility: Soluble in sterile water or appropriate laboratory buffer
Regulatory Status
Cargrilintide has not been evaluated or approved by the U.S. Food and Drug Administration (FDA) for any medical use. Any descriptions provided are for informational and educational purposes only.
Safety Information
Handle in a laboratory environment with appropriate protective equipment.
Do not ingest, inject, or administer to humans or animals.
Follow all institutional safety protocols when handling research peptides.
Disclaimer
This product is sold for laboratory research use only. It is not a drug, food, or cosmetic and should not be misbranded, repackaged, or resold as such. By purchasing or using this material, the buyer acknowledges and agrees to these conditions.
What is Cagrilintide?
Cagrilintide (also known as AM833 or NNC0174-0833) is an investigational long-acting synthetic analog of amylin, a pancreatic hormone co-secreted with insulin that regulates appetite and glucose homeostasis. Developed by Novo Nordisk, it's primarily being studied for obesity and type 2 diabetes management, either as monotherapy or in combination with semaglutide (a GLP-1 receptor agonist) under the name CagriSema. Unlike short-acting amylin analogs like pramlintide (which requires multiple daily doses), cagrilintide's lipidation enables once-weekly subcutaneous administration and extended half-life (~8 days in humans). As of November 2025, it's not yet FDA-approved but has shown robust results in phase 3 trials, with a dedicated monotherapy program (RENEW) set to start in Q4 2025.
Key Benefits of Cagrilintide
Cagrilintide targets multiple metabolic pathways for sustained effects, outperforming placebo and some approved therapies in weight reduction and glycemic control. Benefits are most pronounced in people with overweight/obesity (BMI ≥27 kg/m² with comorbidities or ≥30 kg/m²) and/or type 2 diabetes. Here's a summary based on recent clinical data:
Benefit | Description | Supporting Evidence |
|---|---|---|
Significant Weight Loss | Promotes 6–12% body weight reduction as monotherapy; up to 20%+ when combined with semaglutide, with 60% of users achieving ≥20% loss. Reduces waist circumference, visceral fat, and caloric intake. | Phase 3 REDEFINE 1 sub-analysis (2025): 11.8% loss (12.5 kg) vs. 2.3% placebo after 68 weeks; 31.6% achieved ≥15% loss. CagriSema arm: 20.4% loss vs. 3.0% placebo. |
Appetite Suppression and Satiety | Enhances fullness signals in the brain (hypothalamus), reduces hunger/cravings (especially for high-fat/sugar foods), and slows gastric emptying for prolonged meal satisfaction. | Dose-finding phase 2 trial: Reduced daily caloric intake; superior to liraglutide in satiety scores. Animal models: -9.6% weight loss at 10 nmol/kg. |
Improved Glycemic Control | Lowers HbA1c, postprandial glucose, and glucagon; increases time in target glucose range (3.9–10.0 mmol/L). Beneficial for type 2 diabetes. | Phase 2 trial in T2D: HbA1c reduction of -1.2% with CagriSema vs. -0.9% semaglutide; 88.9% time in range vs. 76.2%. |
Cardiometabolic Improvements | Enhances insulin sensitivity, reduces lipids (e.g., triglycerides), and lowers cardiovascular risk markers; potential benefits for NAFLD and hypertension. | REDEFINE 1 (2025): Broader metabolic benefits including lower blood pressure and improved lipid profiles; no QTc prolongation risk. |
Sustained, Long-Term Effects | Supports maintenance of weight loss beyond treatment; complementary to lifestyle interventions. | Phase 2: 10.8% loss sustained at 4.5 mg dose; meta-analysis: Superior to semaglutide alone in 6-month trials. |
These effects are additive when combined with GLP-1 agonists like semaglutide, targeting complementary pathways for greater efficacy than monotherapy options like liraglutide or tirzepatide in some models.
Mechanism of Action
Cagrilintide acts as a non-selective agonist at amylin receptors (AMYR) and calcitonin receptors in the brain (e.g., hypothalamus, area postrema) and periphery. It mimics amylin's natural roles:
Central effects: Suppresses appetite via satiety signaling and reduces food reward/craving.
Peripheral effects: Delays gastric emptying, inhibits postprandial glucagon secretion, and enhances insulin sensitivity without stimulating insulin release. This differs from GLP-1 agonists (which focus on gut-brain incretin pathways), providing synergistic benefits in combinations like CagriSema. In rats, a 3 nmol/kg dose reduces food intake for 48–60 hours.